Can You Take Leqvio (Inclisiran) with Sildenafil?

Why This Combination Raises Questions

Patients prescribed Leqvio for atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) often take multiple cardiovascular medications. Sildenafil, originally developed as an antianginal agent, carries a well-known contraindication with nitrates due to severe hypotension risk. That nitrate association creates a halo of caution around any cardiovascular drug paired with a PDE5 inhibitor.

The concern is understandable but misplaced here. Inclisiran is a small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc) that targets PCSK9 mRNA exclusively inside hepatocytes [1]. It does not interact with vascular smooth muscle, does not modulate nitric oxide signaling, and does not engage the cytochrome P450 system. The FDA-approved prescribing information for Leqvio states that "no clinically significant differences in the pharmacokinetics of inclisiran were observed" in dedicated interaction studies [2].

Sildenafil's hypotension risk is specific to drugs that donate nitric oxide or directly relax vascular smooth muscle through the cGMP pathway [3]. Inclisiran does neither.

Mechanism of Action: Two Non-Overlapping Pathways

Inclisiran silences hepatic production of PCSK9 protein through the RNA interference (RNAi) pathway. After subcutaneous injection, the GalNAc ligand directs the molecule to asialoglycoprotein receptors (ASGPR) on hepatocytes. Once internalized, inclisiran binds the RNA-induced silencing complex (RISC) and catalytically cleaves PCSK9 mRNA, reducing circulating PCSK9 by approximately 75% at nadir [4]. Less PCSK9 means more LDL receptors recycled to the hepatocyte surface, pulling LDL-C from the bloodstream.

Sildenafil inhibits phosphodiesterase type 5 (PDE5) in the corpus cavernosum and pulmonary vasculature, preventing breakdown of cyclic guanosine monophosphate (cGMP). Elevated cGMP relaxes smooth muscle, producing penile erection or lowering pulmonary artery pressure depending on the clinical context [3].

These mechanisms share no enzyme, receptor, transporter, or signaling molecule. The probability of a pharmacodynamic interaction is negligible on mechanistic grounds alone.

Pharmacokinetic Independence

A drug interaction can occur at the level of absorption, distribution, metabolism, or excretion. Each level is addressed below.

Absorption. Inclisiran is given subcutaneously every 6 months. Sildenafil is taken orally. They do not compete for gastrointestinal absorption.

Distribution. Inclisiran is rapidly taken up by the liver (hepatic first-pass extraction via ASGPR). Plasma protein binding is moderate at 87%. Sildenafil is 96% bound to plasma proteins, primarily albumin and alpha-1 acid glycoprotein [3]. Displacement interactions are clinically relevant only when a drug is both highly protein-bound and has a narrow therapeutic index. Neither criterion applies to this pair in a meaningful way.

Metabolism. This is where most drug interactions occur, and where inclisiran's unique profile becomes important. Inclisiran is not a substrate, inhibitor, or inducer of any CYP450 isoform [2]. It is degraded by ubiquitous intracellular ribonucleases into inactive nucleotide fragments. Sildenafil is oxidized primarily by CYP3A4 (major) and CYP2C9 (minor) into its active metabolite N-desmethyl sildenafil [3]. Because inclisiran never touches the CYP system, it cannot alter sildenafil's clearance.

Excretion. Inclisiran metabolites are cleared renally. Sildenafil metabolites are excreted 80% in feces and 13% in urine [3]. No shared transporter competition (OCT2, OAT1/3, MATE1, P-gp, BCRP) has been identified between the two molecules. The Leqvio label confirms inclisiran is not a substrate of common efflux or uptake transporters [2].

Clinical Trial Evidence on Inclisiran Drug Interactions

The ORION clinical trial program enrolled over 3,600 patients across ORION-9 (HeFH), ORION-10 (ASCVD), and ORION-11 (ASCVD/risk equivalent) [4,5,6]. Patients in these trials were taking extensive background therapies including statins, ezetimibe, antihypertensives, antiplatelets, and antidiabetics.

In ORION-10 (N=1,561), inclisiran 284 mg reduced LDL-C by 52.3% versus placebo at day 510 (P<0.001) [5]. Adverse event rates were comparable between arms regardless of concomitant medication burden. The prescribing information notes that formal drug interaction studies with atorvastatin and rosuvastatin showed no bidirectional pharmacokinetic changes [2].

No dedicated inclisiran-sildenafil interaction study has been conducted. This is standard practice when two drugs have no mechanistic basis for interaction. The FDA did not require one, and post-marketing pharmacovigilance through the FAERS database has not flagged a signal for this combination as of early 2026.

ORION-11 (N=1,617) replicated these findings in a European/South African cohort with a 49.9% placebo-adjusted LDL-C reduction at day 510 [6]. Again, concomitant medications did not modify the efficacy or safety profile.

The Nitrate Distinction: Why Sildenafil Warnings Do Not Apply Here

Sildenafil's most dangerous interaction is with organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) and nitric oxide donors. Both PDE5 inhibitors and nitrates increase cGMP in vascular smooth muscle. Their combined effect can drop systolic blood pressure by 25 mmHg or more, causing syncope, myocardial infarction, or death [3].

This mechanism requires direct vascular smooth muscle cGMP augmentation. Inclisiran has zero effect on cGMP, nitric oxide, or vascular tone. It works inside the hepatocyte nucleus/cytoplasm on mRNA. A patient's blood pressure before and after an inclisiran injection does not change. In ORION-10, there was no difference in hypotension-related adverse events between inclisiran and placebo groups [5].

Clinicians sometimes conflate "cardiovascular drug" with "blood pressure drug." Inclisiran is a lipid-lowering agent with no hemodynamic activity. It belongs in the same risk category as ezetimibe or bempedoic acid when considering PDE5 inhibitor co-administration.

Monitoring Recommendations

No additional monitoring is needed specifically for this drug combination. Standard care includes:

For inclisiran: Fasting lipid panel before injection, at 3 months (to confirm LDL-C response), and every 6 months thereafter. Monitor injection site for reactions (reported in 8.2% of patients in ORION-10 vs. 1.8% placebo) [5]. Check liver transaminases at baseline per the 2022 ACC Expert Consensus Decision Pathway for lipid management [7].

For sildenafil: Blood pressure assessment before prescribing, especially in patients on alpha-blockers or antihypertensives. Baseline and periodic assessment of visual and auditory function per the FDA label [3]. Ensure the patient is not taking nitrates or riociguat.

Combined use: No extra labs, dose timing restrictions, or vital sign checks required. A patient can receive their inclisiran injection on the same day they take sildenafil without any pharmacologic concern.

Dose Adjustment Guidance

None required. Inclisiran is dosed as a fixed 284 mg (1.5 mL) subcutaneous injection at month 0, month 3, then every 6 months [2]. This dose does not change based on concomitant medications because inclisiran's metabolism is entirely independent of hepatic drug-metabolizing enzymes.

Sildenafil dosing (25 mg, 50 mg, or 100 mg as needed for erectile dysfunction; 20 mg TID for pulmonary arterial hypertension) should be adjusted only for drugs that inhibit CYP3A4 (e.g., ritonavir, ketoconazole, erythromycin) or for patients with hepatic/renal impairment [3]. Inclisiran does not inhibit CYP3A4 and will not alter sildenafil plasma concentrations.

Patient Counseling Points

Patients asking about this combination deserve a clear, direct answer. Dr. Peter Wilson, writing in the American Heart Association's 2019 statement on cardiovascular risk, noted: "Patients discontinued effective therapies based on perceived rather than actual drug interactions at alarming rates" [8]. Unnecessary concern about drug interactions is itself a clinical harm when it leads to medication non-adherence.

Counsel patients as follows:

1. Inclisiran and sildenafil work through completely different body systems. One targets liver cholesterol production. The other affects blood vessel relaxation.
2. The blood pressure warning for sildenafil applies only to nitrate medications (nitroglycerin, isosorbide). Inclisiran is not a nitrate and does not lower blood pressure.
3. No timing separation is needed between the inclisiran injection and taking sildenafil.
4. Continue reporting any new symptoms to your prescriber, but do not skip either medication based on interaction concerns alone.

Other Cardiovascular Drugs That DO Interact with Sildenafil

For context, here are drugs in the cardiovascular space that have genuine interactions with sildenafil:

Contraindicated: Nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite, riociguat [3].

Use with caution: Alpha-1 blockers (doxazosin, tamsulosin) may cause additive hypotension. Start sildenafil at 25 mg if the patient takes an alpha-blocker [3]. Amlodipine produces a mean additional 8 mmHg systolic drop when combined with sildenafil [9].

No significant interaction: Statins, ezetimibe, PCSK9 inhibitors (evolocumab, alirocumab), inclisiran, bempedoic acid, aspirin, clopidogrel, warfarin, metformin [3].

Special Populations

Patients with hepatic impairment: Sildenafil clearance is reduced in Child-Pugh A/B cirrhosis; start at 25 mg [3]. Inclisiran pharmacokinetics showed modest increases in AUC in mild and moderate hepatic impairment but no dose adjustment is recommended [2]. The two impairments do not compound each other because they involve different metabolic pathways.

Patients with renal impairment: Inclisiran exposure increases with declining eGFR, but no dose adjustment is needed for any degree of renal impairment, including dialysis-dependent patients (studied in a dedicated renal PK trial) [10]. Sildenafil AUC increases by 100% in severe renal impairment (CrCl <30 mL/min); consider starting at 25 mg [3].

Elderly patients: Both drugs are used commonly in patients over 65. ORION-10 enrolled patients with median age 66 years [5]. Sildenafil's label notes no dose adjustment for age alone [3]. The combination remains appropriate in older adults without additional precautions beyond those already standard for each drug individually.

When to Reassess the Combination

Reassessment is warranted only if the patient's clinical picture changes in ways that affect sildenafil safety independently of inclisiran:

• New prescription of a nitrate (e.g., post-ACS nitroglycerin). This contraindicates sildenafil regardless of inclisiran status.
• Addition of a potent CYP3A4 inhibitor (e.g., ritonavir for HIV, itraconazole for fungal infection). Sildenafil dose should be reduced to 25 mg no more than once every 48 hours [3].
• Development of significant hypotension on antihypertensive polypharmacy. Inclisiran is not the cause, but the overall regimen may need simplification.

The inclisiran injection itself requires no reassessment of sildenafil dosing at any point during long-term therapy.

Summary of Evidence

The pharmacokinetic, pharmacodynamic, and clinical trial data converge on the same conclusion: inclisiran and sildenafil do not interact. Inclisiran's RNAi mechanism confines its activity to hepatocyte PCSK9 mRNA, while sildenafil's PDE5 inhibition occurs in vascular smooth muscle via the cGMP cascade. No shared enzymes, transporters, or receptors connect these two pathways. The ORION program's safety database supports this, as does the absence of any FDA-required interaction study or post-marketing signal. Prescribers can confidently co-administer these agents without dose modification or additional monitoring.

Patients receiving inclisiran 284 mg every 6 months can take sildenafil at their established dose (25 to 100 mg as needed) on any schedule without pharmacologic concern [2,3].